Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Jacqueline T. Brown"'
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Emilie Elise Hitron, Greta Anne Russler, Lauren Yantorni, Sarah Caulfield, Jacqueline T. Brown, Jamie M. Goldman, Bassel Nazha, Bradley C. Carthon, Wayne B. Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 52-57 (2022)
Introduction: There are three combination immune checkpoint inhibitor (ICI)–based regimens in the first-line setting for metastatic renal cell carcinoma (mRCC). Currently, there is limited real-world data for clinical outcomes and toxicity in mRCC
Externí odkaz:
https://doaj.org/article/3b523ccfbd2e4ae9ba07ac843f39a4e8
Autor:
Agreen Hadadi, Harris B. Krause, Andrew Elliott, Jacqueline T. Brown, Bassel Nazha, Lara R. Harik, Bradley C. Carthon, Benjamin Miron, Chadi Nabhan, Pedro C. Barata, Mohamed Saleh, Yuanquan Yang, Rana R. McKay, Mehmet A. Bilen
Publikováno v:
Cancers, Vol 15, Iss 24, p 5721 (2023)
Background: Recent data suggests that HER2-targeted treatment is efficacious in urothelial carcinoma (UC). We investigated the genomic, transcriptomic, and immune landscapes and clinical outcomes in UC segmented by ERBB2 expression. Methods: NextGen
Externí odkaz:
https://doaj.org/article/c55a5991ac2547e18846764f7fefca65
Autor:
Jacqueline T. Brown, Vikram M. Narayan, Shreyas S. Joshi, Lara Harik, Ashesh B. Jani, Mehmet Asim Bilen
Publikováno v:
Cancer Treatment and Research Communications, Vol 34, Iss , Pp 100663- (2023)
Urothelial carcinoma accounts for approximately 90% of all bladder cancer diagnoses. Localized, muscle-invasive disease is often managed with a multidisciplinary approach including either neoadjuvant chemotherapy (NAC) followed by radical cystectomy
Externí odkaz:
https://doaj.org/article/2d15cfb2dd024c29b7b884d6ad9c8807
Autor:
Tony Zibo Zhuang, Lara Harik, Seth Force, Agreen Hadadi, Mehmet Asim Bilen, Jacqueline T. Brown, Bradley C. Carthon, Jamie Goldman, Omer Kucuk, Viraj A. Master, Bassel Nazha
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received
Externí odkaz:
https://doaj.org/article/82d35e8cfd2f4bd2a107b982a151d13f
Autor:
T. Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, Dylan J. Martini, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Wayne Harris, Mehmet Asim Bilen, Bassel Nazha
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Immune-oncologic (IO) therapy has revolutionized the treatment and management of oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability to endogenously clear malignant cells, however, this activation can also lead to
Externí odkaz:
https://doaj.org/article/b0ec3f5e0a72497faac55787d11fe1bc
Publikováno v:
Biology Open, Vol 10, Iss 10 (2021)
Pom152 is a transmembrane protein within the nuclear pore complex (NPC) of fungi that is important for NPC assembly and structure. Pom152 is comprised of a short amino-terminal region that remains on the cytosolic side of the nuclear envelope (NE) an
Externí odkaz:
https://doaj.org/article/633e99f0771f4c658bc7c38e92cd80c4
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Externí odkaz:
https://doaj.org/article/9162907753ca46b98f276622972a2ce3
Autor:
T. Anders Olsen, Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Bassel Nazha, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between Afr
Externí odkaz:
https://doaj.org/article/3aa9b41eb0064fb78cd9cab2b089a0c5
Autor:
Tony Zibo Zhuang, Katherine Case, Timothy Anders Olsen, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Jamie Goldman, Wayne Harris, Mehmet Asim Bilen, Bassel Nazha
Publikováno v:
Cancers, Vol 14, Iss 12, p 2867 (2022)
Immune checkpoint inhibitors (ICI) are now the bedrock for the treatment of metastatic renal cell carcinoma (RCC). Clear cell RCC (ccRCC) represents the most common subtype of this malignancy. Herein, we explore the therapeutic landscape of ccRCC by
Externí odkaz:
https://doaj.org/article/d75f17cbc8454f77a2c557c6f1deafda
Autor:
Mehmet A. Bilen, James F. Jiang, Caroline S. Jansen, Jacqueline T. Brown, Lara R. Harik, Aarti Sekhar, Haydn Kissick, Shishir K. Maithel, Omer Kucuk, Bradley Carthon, Viraj A. Master
Publikováno v:
Frontiers in Oncology, Vol 10 (2021)
IntroductionCabozantinib (XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR and CABOSUN trials, c
Externí odkaz:
https://doaj.org/article/9bd82e94fe14462488e08962f8af3568